Organovo Holdings, Inc. (ONVO)

[rayank]

Growing acceptance: People were once resistant but now are more accepting. Yes, we could be talking about marijuana. However, the statement also applies to 3-D bioprinted tissues. Any conversation about these bioprinted tissues needs to include Organovo.

Organovo first rolled out a 3-D bioprinted human liver tissue in 2014. The company launched its second product, human kidney tissue, earlier this year. Organovo's main customers were and are pharmaceutical companies looking to detect toxicity as early in the drug discovery and development process as possible.

Convincing scientists who were accustomed to using animal models and in vitro two-dimensional human tissue wasn't an easy task. Organovo is steadily accomplishing that goal, though. The company now counts 10 of the top 25 global pharmaceutical companies as customers.

Organovo is still tiny, just like most marijuana stocks. However, the company's revenue growth is impressive -- sales soared 358% year over year last quarter. Other products and services will be rolled out in the next few years, which should allow Organovo to keep growing revenue at a solid rate.

Forget Marijuana Stocks: Buy These 3 Biotech Stocks Instead

http://www.fool.com/investing/2016/12/18/forget-marijuana-stocks-buy-these-3-biotech-stocks.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2